Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 29;5(5):e1108513. doi: 10.1080/2162402X.2015.1108513

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 3. — NK cells exhibit resistance to TMZ-induced apoptosis. (A and C) Apoptosis induced by TMZ treatment in NK and CD8⁺ T cells from PBLs of naive mice (n = 20). EA and LA represent early and late apoptosis, respectively. (B) Early and late apoptosis of Abcc3⁺ and Abcc3⁻ NK cells treated in vitro with 1 μM TMZ. (D) Western blot analysis and densitometric quantification of pAkt in blood immune-separated NK and CD8⁺ T cells of naïve mice (n = 20) treated with 1 μM TMZ or DMSO. (E) Intracellular staining of pAkt in blood-derived Abcc3⁺NK and Abcc3⁺CD8⁺ T cells from glioma-bearing mice (n = 4/group) at 72 h. (F) Representative dot plots showing apoptosis in NK cells treated for 4 h in vitro with 1 μM TMZ and 25 μM Abcc3 inhibitor added to the medium 30 min before (pre-MK571) or after (post MK571) the pharmacological treatment. *p < 0.01, **p < 0.001 and ***p < 0.0001.